1,610 results on '"DE CATERINA, R."'
Search Results
2. Impaired adenylate cyclase signaling in acute myocardial ischemia: Impact on effectiveness of P2Y12 receptor antagonists
- Author
-
Imam, H., Nguyen, T.H., De Caterina, R., Nooney, V.B., Chong, C.-R., Horowitz, J.D., and Chirkov, Y.Y.
- Published
- 2019
- Full Text
- View/download PDF
3. Baseline demographic and clinical characteristics as predictors of adverse outcomes to improve management of patients with AF receiving edoxaban: a subanalysis of the ETNA-AF registry
- Author
-
Morrone, D, primary, Chao, T, additional, Chen, C, additional, Choi, E, additional, De Groot, J, additional, Kirchhof, P, additional, Pecen, L, additional, Tse, H, additional, Unverdorben, M, additional, and De Caterina, R, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Persistence to edoxaban treatment in patients with atrial fibrillation: Analysis from the Global ETNA-AF program
- Author
-
Diemberger, I, primary, Chen, C, additional, Choi, J, additional, De Groot, J, additional, Kirchhof, P, additional, Pecen, L, additional, Unverdorben, M, additional, Wang, C, additional, Yamashita, T, additional, and De Caterina, R, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Empagliflozin restores autophagy and ameliorates ponatinib-induced cardiomyocyte death
- Author
-
Madonna, R, primary, Ghelardoni, S, additional, Moscato, S, additional, Mattii, L, additional, Barachini, S, additional, Novo, G, additional, Zucchi, R, additional, and De Caterina, R, additional
- Published
- 2023
- Full Text
- View/download PDF
6. Chronic thromboembolic disease is associated with exercise-induced pulmonary hypertension and functional right ventricle deterioration
- Author
-
Madonna, R, primary, Morganti, R, additional, Badagliacca, R, additional, Biondi, F, additional, Alberti, M, additional, Vizza, C D, additional, and De Caterina, R, additional
- Published
- 2023
- Full Text
- View/download PDF
7. Effect of perceived and objectively-assessed frailty on outcomes in edoxaban-treated patients with atrial fibrillation: data from the ETNA-AF-Europe 4-year follow-up
- Author
-
Fumagalli, S, primary, Diemberger, I, additional, Bakhai, A, additional, Pecen, L, additional, Lamparter, M, additional, Kirchhof, P, additional, and De Caterina, R, additional
- Published
- 2023
- Full Text
- View/download PDF
8. Inflammatory activity of vulnerable plaques in asymptomatic, non-hemodynamically significant carotid artery stenoses: preliminary results of the carotid artery multi-modality imaging prognostic study
- Author
-
Masini, G, primary, Gargani, L, additional, Baldini, M, additional, Aghakhanyan, G, additional, Volterrani, D, additional, Erba, P A, additional, Marciano, A, additional, Napoli, V, additional, Cosottini, M, additional, Lucchi, G, additional, D'angelo, G, additional, Morizzo, C, additional, Orlandi, G, additional, Palombo, C, additional, and De Caterina, R, additional
- Published
- 2023
- Full Text
- View/download PDF
9. Imaging signs of vulnerability, neurological events and cognitive impairment in asymptomatic carotid artery stenosis: results from the Carotid Artery Multi-modality imaging Prognostic (CAMP) study
- Author
-
Gargani, L, primary, Masini, G, additional, Baldini, M, additional, Napoli, V, additional, Orlandi, G, additional, Lucchi, G, additional, Totaro, P, additional, D'amelio, C, additional, Galeotti, G G, additional, Ghicopulos, I, additional, Nilsson, I, additional, Goncalves, I, additional, Palombo, C, additional, Cosottini, M, additional, and De Caterina, R, additional
- Published
- 2023
- Full Text
- View/download PDF
10. Detecting the vulnerable carotid plaque: The Carotid Artery Multimodality imaging Prognostic study design
- Author
-
Gargani, L, Baldini, M, Berchiolli, R, Bort, I, Casolo, G, Chiappino, D, Cosottini, M, D'Angelo, G, De Santis, M, Erba, P, Fabiani, I, Fabiani, P, Gabbriellini, I, Galeotti, G, Ghicopulos, I, Goncalves, I, Lapi, S, Masini, G, Morizzo, C, Napoli, V, Nilsson, J, Orlandi, G, Palombo, C, Pieraccini, F, Ricci, S, Siciliano, G, Slart, R, De Caterina, R, Gargani L., Baldini M., Berchiolli R., Bort I. R., Casolo G., Chiappino D., Cosottini M., D'Angelo G., De Santis M., Erba P., Fabiani I., Fabiani P., Gabbriellini I., Galeotti G. G., Ghicopulos I., Goncalves I., Lapi S., Masini G., Morizzo C., Napoli V., Nilsson J., Orlandi G., Palombo C., Pieraccini F., Ricci S., Siciliano G., Slart R. H. J. A., De Caterina R., Gargani, L, Baldini, M, Berchiolli, R, Bort, I, Casolo, G, Chiappino, D, Cosottini, M, D'Angelo, G, De Santis, M, Erba, P, Fabiani, I, Fabiani, P, Gabbriellini, I, Galeotti, G, Ghicopulos, I, Goncalves, I, Lapi, S, Masini, G, Morizzo, C, Napoli, V, Nilsson, J, Orlandi, G, Palombo, C, Pieraccini, F, Ricci, S, Siciliano, G, Slart, R, De Caterina, R, Gargani L., Baldini M., Berchiolli R., Bort I. R., Casolo G., Chiappino D., Cosottini M., D'Angelo G., De Santis M., Erba P., Fabiani I., Fabiani P., Gabbriellini I., Galeotti G. G., Ghicopulos I., Goncalves I., Lapi S., Masini G., Morizzo C., Napoli V., Nilsson J., Orlandi G., Palombo C., Pieraccini F., Ricci S., Siciliano G., Slart R. H. J. A., and De Caterina R.
- Abstract
BackgroundCarotid artery disease is highly prevalent and a main cause of ischemic stroke and vascular dementia. There is a paucity of information on predictors of serious vascular events. Besides percentage diameter stenosis, international guidelines also recommend the evaluation of qualitative characteristics of carotid artery disease as a guide to treatment, but with no agreement on which qualitative features to assess. This inadequate knowledge leads to a poor ability to identify patients at risk, dispersion of medical resources, and unproven use of expensive and resource-consuming techniques, such as magnetic resonance imaging, positron emission tomography, and computed tomography.ObjectivesThe Carotid Artery Multimodality imaging Prognostic (CAMP) study will: prospectively determine the best predictors of silent and overt ischemic stroke and vascular dementia in patients with asymptomatic subcritical carotid artery disease by identifying the noninvasive diagnostic features of the 'vulnerable carotid plaque'; assess whether 'smart' use of low-cost diagnostic methods such as ultrasound-based evaluations may yield at least the same level of prospective information as more expensive techniques.Study designWe will compare the prognostic/predictive value of all proposed techniques with regard to silent or clinically manifest ischemic stroke and vascular dementia. The study will include ≥300 patients with asymptomatic, unilateral, intermediate degree (40-60% diameter) common or internal carotid artery stenosis detected at carotid ultrasound, with a 2-year follow-up. The study design has been registered on Clinicaltrial.gov on December 17, 2020 (ID number NCT04679727).
- Published
- 2022
11. P281 CARDIAC RICHTER‘S SYNDROME: A RARE CASE OF CHRONIC LYMPHOCYTIC LEUKAEMIA TRANSFORMATION
- Author
-
Guarnieri, E, primary, Ridolfi, L, additional, Castiglione, V, additional, Donati, V, additional, and De Caterina, R, additional
- Published
- 2023
- Full Text
- View/download PDF
12. Post receptor determinants of acute platelet response to clopidogrel in patients with symptomatic myocardial ischemia
- Author
-
Nooney, V.B., Hurst, N.L., Chirkov, Y.Y., De Caterina, R., and Horowitz, J.D.
- Published
- 2015
- Full Text
- View/download PDF
13. Two-year outcomes of patients with atrial fibrillation and heart failure: the ETNA-AF-Europe registry
- Author
-
Ameri, P, primary, Schnabel, R B, additional, Pecen, L, additional, Diemberger, I, additional, Gwechenberger, M, additional, Siller-Matula, J, additional, Kirchhof, P, additional, and De Caterina, R, additional
- Published
- 2022
- Full Text
- View/download PDF
14. Clinical outcomes in patients with atrial fibrillation with or without concomitant diabetes after two years of edoxaban treatment: ETNA-AF-Europe registry
- Author
-
Patti, G, primary, Pecen, L, additional, Casalnuovo, G, additional, Kirchhof, P, additional, and De Caterina, R, additional
- Published
- 2022
- Full Text
- View/download PDF
15. Two-year effectiveness and safety outcomes in 27,333 edoxaban-treated patients with and without a history of major bleeding from the Global ETNA-AF programme
- Author
-
Russo, V, primary, Wang, C C, additional, Unverdorben, M, additional, Yamashita, T, additional, Pecen, L, additional, Borrow, A, additional, Chen, C, additional, Kirchhof, P, additional, and De Caterina, R, additional
- Published
- 2022
- Full Text
- View/download PDF
16. The real-world effectiveness and safety of edoxaban treatment in 27,333 Global ETNA-AF programme patients with and without a history of heart failure
- Author
-
Siller-Matula, J, primary, Unverdorben, M, additional, Wang, C C, additional, Koretsune, Y, additional, Pecen, L, additional, Borrow, A, additional, Chen, C, additional, Kirchhof, P, additional, and De Caterina, R, additional
- Published
- 2022
- Full Text
- View/download PDF
17. Revascularization strategies versus optimal medical therapy in chronic coronary syndrome: a systematic review and network meta-analysis
- Author
-
Galli, M, primary, Benenati, S, additional, Zito, A, additional, Capodanno, D, additional, Biondi-Zoccai, G, additional, Ortega-Paz, L, additional, D'Amario, D, additional, Porto, I, additional, Burzotta, F, additional, Trani, C, additional, De Caterina, R, additional, Escaned, J, additional, Gaudino, M, additional, Angiolillo, D J, additional, and Crea, F, additional
- Published
- 2022
- Full Text
- View/download PDF
18. Real-world effectiveness and safety of edoxaban in patients with and without a history of ischaemic stroke: results from the ETNA-AF programme
- Author
-
De Caterina, R, primary, Unverdorben, M, additional, Lee, B C, additional, Yamashita, T, additional, Lin, W S, additional, Wang, C C, additional, Pecen, L, additional, Borrow, A, additional, Chen, C, additional, and Kirchhof, P, additional
- Published
- 2022
- Full Text
- View/download PDF
19. The association between dyslipidaemia treatment and the risk of clinical events in edoxaban-treated patients with atrial fibrillation: insights from the 2-year follow-up of ETNA-AF-Europe
- Author
-
De Vries, T A C, primary, Pecen, L, additional, Komen, J J, additional, De Groot, J R, additional, Kirchhof, P, additional, and De Caterina, R, additional
- Published
- 2022
- Full Text
- View/download PDF
20. Comparison of the efficacy and safety between different oral P2Y12 receptor inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis
- Author
-
Lepone, A, primary, Castiglione, V, additional, Gentile, F, additional, Scalera, S, additional, Negro, F, additional, Ridolfi, L, additional, Favilli, M, additional, Italiano, A, additional, Mazzola, M, additional, Masaracchia, G, additional, Mancini, S, additional, Guarini, G, additional, Masini, G, additional, De Caterina, R, additional, and Morrone, D, additional
- Published
- 2022
- Full Text
- View/download PDF
21. Perceived frailty and clinical outcomes in men and women with atrial fibrillation treated with edoxaban: insights from the 2-year follow-up of ETNA-AF-Europe
- Author
-
De Vries, T A C, primary, Pecen, L, additional, Komen, J J, additional, Diemberger, I, additional, Fumagalli, S, additional, De Groot, J R, additional, Kirchhof, P, additional, and De Caterina, R, additional
- Published
- 2022
- Full Text
- View/download PDF
22. Empagliflozin alleviates diabetic cardiomyopathy via inhibiting excessive autophagy and adverse remodeling in type 1 diabetic mice
- Author
-
Madonna, R, primary, Moscato, S, additional, Cufaro, M, additional, Pieragostino, D, additional, Mattii, L, additional, Del Boccio, P, additional, Ghelardoni, S, additional, Zucchi, R, additional, and De Caterina, R, additional
- Published
- 2022
- Full Text
- View/download PDF
23. Neuroimaging evaluation of unilateral asymptomatic carotid plaque ulceration: preliminary results of the Carotid Artery Multimodality imaging Prognostic study
- Author
-
Masini, G, primary, Gargani, L, additional, Napoli, V, additional, Cosottini, M, additional, Chiappino, D, additional, Orlandi, G, additional, D'Amelio, C, additional, Todaro, P, additional, Galeotti, G, additional, Bort, I R, additional, Baldini, M, additional, Aghakhanyan, G, additional, Erba, P, additional, Palombo, C, additional, and De Caterina, R, additional
- Published
- 2022
- Full Text
- View/download PDF
24. D‐dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation – observations from the ARISTOTLE trial
- Author
-
Christersson, C., Wallentin, L., Andersson, U., Alexander, J.H., Ansell, J., De Caterina, R., Gersh, B.J., Granger, C.B., Hanna, M., Horowitz, J.D., Huber, K., Husted, S., Hylek, E.M., Lopes, R.D., and Siegbahn, A.
- Published
- 2014
- Full Text
- View/download PDF
25. Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice:: GLORIA-AF Registry
- Author
-
Lip G. Y. H., Kotalczyk A., Teutsch C., Diener H. -C., Dubner S. J., Halperin J. L., Ma C. -S., Rothman K. J., Marler S., Gurusamy V. K., Huisman M. V., Abban D. W., Aziz E., Kalan M. B., Abdul N., Backes L. M., Bradman D., Abud A. M., Badings E., Brautigam D., Adams F., Bagni E., Breton N., Addala S., Baker S. H., Brouwers P. J. A. M., Adragao P., Bala R., Browne K., Ageno W., Baldi A., Cortada J. B., Aggarwal R., Bando S., Bruni A., Agosti S., Banerjee S., Brunschwig C., Agostoni P., Bank A., Buathier H., Aguilar F., Esquivias G. B., Buhl A., Linares J. A., Barr C., Bullinga J., Aguinaga L., Bartlett M., Cabrera J. W., Ahmed J., Basic Kes V., Caccavo A., Aiello A., Baula G., Cai S., Ainsworth P., Behrens S., Caine S., Aiub J. R., Bell A., Calo L., Al-Dallow R., Benedetti R., Calvi V., Alderson L., Mazuecos J. B., Sanchez M. C., Velasco J. A. A., Benhalima B., Candeias R., Alexopoulos D., Bergler-Klein J., Capuano V., Manterola F. A., Berneau J. -B., Capucci A., Aliyar P., Bernstein R. A., Caputo R., Alonso D., Berrospi P., Rizo T. C., da Costa F. A. A., Berti S., Cardona F., Amado J., Berz A., da Costa Darrieux F. C., Amara W., Best E., Vera Y. C. D., Amelot M., Bettencourt P., Carolei A., Amjadi N., Betzu R., Carreno S., Ammirati F., Bhagwat R., Carvalho P., Andrade M., Bhatta L., Cary S., Andrawis N., Biscione F., Casu G., Annoni G., Bisignani G., Cavallini C., Ansalone G., Black T., Cayla G., Ariani M. K., Bloch M. J., Celentano A., Arias J. C., Bloom S., Cha T. -J., Armero S., Blumberg E., Cha K. S., Arora C., Bo M., Chae J. K., Aslam M. S., Bohmer E., Chalamidas K., Asselman M., Bollmann A., Challappa K., Audouin P., Bongiorni M. G., Chand S. P., Augenbraun C., Boriani G., Chandrashekar H., Aydin S., Boswijk D. J., Chartier L., Bott J., Chatterjee K., Ayryanova I., Bottacchi E., Ayala C. A. C., Cheema A., Davis G., Evonich R., Davy J. -M., Evseeva O., Chen L., Dayer M., Ezhov A., Chen S. -A., De Biasio M., Fahmy R., Chen J. H., De Bonis S., Fang Q., Chiang F. -T., De Caterina R., Farsad R., Chiarella F., De Franceschi T., Fauchier L., Chih-Chan L., de Groot J. R., Favale S., Cho Y. K., De Horta J., Fayard M., Choi J. -I., De La Briolle A., Fedele J. L., Choi D. J., de la Pena Topete G., Fedele F., Chouinard G., de Paola A. A. V., Fedorishina O., Chow D. H. -F., de Souza W., Fera S. R., Chrysos D., de Veer A., Ferreira L. G. G., Chumakova G., De Wolf L., Ferreira J., Valenzuela E. J. J. R. C., Decoulx E., Ferri C., Nica N. C., Deepak S., Ferrier A., Cislowski D. J., Defaye P., Ferro H., Clay A., Munoz F. D. -C., Finsen A., Clifford P., Brkljacic D. D., First B., Cohen A., Deumite N. J., Fischer S., Cohen M., Di Legge S., Fonseca C., Cohen S., Diemberger I., Almeida L. F., Colivicchi F., Dietz D., Forman S., Collins R., Dionisio P., Frandsen B., Colonna P., Dong Q., French W., Compton S., dos Santos F. R., Friedman K., Connolly D., Dotcheva E., Friese A., Conti A., Doukky R., Fruntelata A. G., Buenostro G. C., D'Souza A., Fujii S., Coodley G., Dubrey S., Fumagalli S., Cooper M., Ducrocq X., Fundamenski M., Coronel J., Dupljakov D., Furukawa Y., Corso G., Duque M., Gabelmann M., Sales J. C., Dutta D., Gabra N., Cottin Y., Duvilla N., Gadsboll N., Covalesky J., Duygun A., Galinier M., Cracan A., Dziewas R., Gammelgaard A., Crea F., Eaton C. B., Ganeshkumar P., Crean P., Eaves W., Gans C., Crenshaw J., Ebels-Tuinbeek L. A., Quintana A. G., Cullen T., Ehrlich C., Gartenlaub O., Darius H., Eichinger-Hasenauer S., Gaspardone A., Dary P., Eisenberg S. J., Genz C., Dascotte O., Jabali A. E., Georger F., Dauber I., Shahawy M. E., Georges J. -L., Davalos V., Hernandes M. E., Georgeson S., Davies R., Izal A. E., Giedrimas E., Gierba M., Haruna T., Jarmukli N., Ortega I. G., Hayek E., Jeanfreau R. J., Gillespie E., Healey J., Jenkins R. D., Giniger A., Hearne S., Sanchez C. J., Giudici M. C., Heffernan M., Jimenez J., Gkotsis A., Heggelund G., Jobe R., Glotzer T. V., Heijmeriks J. A., Joen-Jakobsen T., Gmehling J., Hemels M., Jones N., Gniot J., Hendriks I., Jorge J. C. M., Goethals P., Henein S., Jouve B., Goldbarg S., Her S. -H., Jung B. C., Goldberg R., Hermany P., Jung K. T., Goldmann B., Del Rio J. E. H., Jung W., Golitsyn S., Higashino Y., Kachkovskiy M., Gomez S., Hill M., Kafkala K., Mesa J. G., Hisadome T., Kalinina L., Gonzalez V. B., Hishida E., Kallmunzer B., Hermosillo J. A. G., Hoffer E., Kamali F., Lopez V. M. G., Hoghton M., Kamo T., Gorka H., Hong K., Kampus P., Gornick C., Hong S., Kashou H., Gorog D., Horbach S., Kastrup A., Gottipaty V., Horiuchi M., Katsivas A., Goube P., Hou Y., Kaufman E., Goudevenos I., Hsing J., Kawai K., Graham B., Huang C. -H., Kawajiri K., Greer G. S., Huckins D., Kazmierski J. F., Gremmler U., Hughes K., Keeling P., Grena P. G., Huizinga A., Saraiva J. F. K., Grond M., Hulsman E. L., Ketova G., Gronda E., Hung K. -C., Khaira A. S., Gronefeld G., Hwang G. -S., Khripun A., Gu X., Ikpoh M., Kim D. -I., Torres I. G. T., Imberti D., Kim Y. H., Guardigli G., Ince H., Kim N. H., Guevara C., Indolfi C., Kim D. K., Guignier A., Inoue S., Kim J. S., Gulizia M., Irles D., Gumbley M., Iseki H., Kim K. S., Gunther A., Israel C. N., Kim J., Ha A., Iteld B., Kinova E., Hahalis G., Iyer V., Klein A., Hakas J., Jackson-Voyzey E., Kmetzo J. J., Hall C., Jaffrani N., Kneller G. L., Han B., Jager F., Knezevic A., Han S., James M., Koh S. M. A., Hargrove J., Jang S. -W., Koide S., Hargroves D., Jaramillo N., Kollias A., Kooistra J. A., Li W., McClure J., Koons J., Li X., McCormack T., Koschutnik M., Lichy C., McGarity W., Kostis W. J., Lieber I., McIntyre H., Kovacic D., Rodriguez R. H. L., McLaurin B., Kowalczyk J., Lin H., Alvaro F., Palomino M., Koziolova N., Melandri F., Kraft P., Liu F., Meno H., Kragten J. A., Liu H., Menzies D., Krantz M., Esperon G. L., Mercader M., Krause L., Navarro N. L., Meyer C., Krenning B. J., Lo E., Meyer B. J., Krikke F., Lokshyn S., Miarka J., Kromhout Z., Lopez A., Mibach F., Krysiak W., Lopez-Sendon J. L., Michalski D., Kumar P., Filho A. M. L., Michel P., Kumler T., Lorraine R. S., Chreih R. M., Kuniss M., Luengas C. A., Luengas A., Mikdadi G., Kuo J. -Y., Luke R., Mikus M., Kuppers A., Luo M., Milicic D., Kurrelmeyer K., Lupovitch S., Militaru C., Kwak C. H., Lyrer P., Minaie S., Laboulle B., Ma C., Minescu B., Labovitz A., Ma G., Mintale I., Ter Lai W., Madariaga I., Mirault T., Lam A., Maeno K., Mirro M. J., Lam Y. Y., Magnin D., Mistry D., Lanas Zanetti F., Maid G., Miu N. V., Landau C., Mainigi S. K., Miyamoto N., Landini G., Makaritsis K., Moccetti T., Lanna Figueiredo E., Malhotra R., Mohammed A., Larsen T., Manning R., Nor A. M., Lavandier K., Manolis A., Mollerus M., LeBlanc J., Hurtado H. A. M., Molon G., Lee M. H., Mantas I., Mondillo S., Lee C. -H., Jattin F. M., Moniz P., Lehman J., Maqueda V., Mont L., Leitao A., Marchionni N., Montagud V., Lellouche N., Ortuno F. M., Montana O., Lelonek M., Santana A. M., Monti C., Lenarczyk R., Martinez J., Moretti L., Lenderink T., Maskova P., Mori K., Gonzalez S. L., Hernandez N. M., Moriarty A., Leong-Sit P., Matsuda K., Morka J., Leschke M., Maurer T., Moschini L., Ley N., Mauro C., Moschos N., Li Z., May E., Mugge A., Mayer N., Mulhearn T. J., Muresan C., Jose E. P., Precoma D. B., Muriago M., Padilla F. G. P., Prelle A., Musial W., Rios V. P., Prodafikas J., Musser C. W., Pajes G., Protasov K., Musumeci F., Pandey A. S., Pye M., Nageh T., Paparella G., Qiu Z., Nakagawa H., Paris F., Quedillac J. -M., Nakamura Y., Park H. W., Raev D., Nakayama T., Park J. S., Grado C. A. R., Nam G. -B., Parthenakis F., Rahimi S., Nanna M., Passamonti E., Raisaro A., Natarajan I., Patel R. J., Rama B., Nayak H. M., Patel J., Ramos R., Naydenov S., Patel M., Ranieri M., Nazlic J., Patrick J., Raposo N., Nechita A. C., Jimenez R. P., Rashba E., Nechvatal L., Paz A., Rauch-Kroehnert U., Negron S. A., Pengo V., Reddy R., Neiman J., Pentz W., Renda G., Neuenschwander F. C., Perez B., Reza S., Neves D., Rios A. M. P., Ria L., Neykova A., Perez-Cabezas A., Richter D., Miguel R. N., Perlman R., Rickli H., Nijmeh G., Persic V., Rieker W., Nizov A., Perticone F., Vera T. R., Campos R. N., Peters T. K., Ritt L. E., Nossan J., Petkar S., Roberts D., Novikova T., Pezo L. F., Briones I. R., Nowalany-Kozielska E., Pflucke C., Escudero A. E. R., Nsah E., Pham D. N., Pascual C. R., Fragoso J. C. N., Phillips R. T., Roman M., Nurgalieva S., Phlaum S., Romeo F., Nuyens D., Pieters D., Ronner E., Nyvad O., Pineau J., Roux J. -F., de Los Rios Ibarra M. O., Pinter A., Rozkova N., O'Donnell P., Pinto F., Rubacek M., O'Donnell M., Pisters R., Rubalcava F., Oh S., Pivac N., Russo A. M., Oh Y. S., Pocanic D., Rutgers M. P., Oh D., Podoleanu C., Rybak K., O'Hara G., Politano A., Said S., Oikonomou K., Poljakovic Z., Sakamoto T., Olivares C., Pollock S., Salacata A., Oliver R., Garcea J. P., Salem A., Ruiz R. O., Poppert H., Bodes R. S., Olympios C., Porcu M., Saltzman M. A., Omaszuk-Kazberuk A., Reino A. P., Salvioni A., Asensi J. O., Prasad N., Vallejo G. S., Fernandez M. S., Sokal A., Tu T. M., Saporito W. F., Yan Y. S. O., Tuininga Y., Sarikonda K., Sotolongo R., Turakhia M., Sasaoka T., de Souza O. F., Turk S., Sati H., Sparby J. A., Turner W., Savelieva I., Spinar J., Tveit A., Scala P. -J., Sprigings D., Tytus R., Schellinger P., Spyropoulos A. C., Valadao C., Scherr C., Stakos D., van Bergen P. F. M. M., Schmitz L., Steinwender C., van de Borne P., Schmitz K. -H., Stergiou G., van den Berg B. J., Schmitz B., Stiell I., van der Zwaan C., Schnabel T., Stoddard M., Van Eck M., Schnupp S., Stoikov A., Vanacker P., Schoeniger P., Streb W., Vasilev D., Schon N., Styliadis I., Vasilikos V., Schwimmbeck P., Su G., Vasilyev M., Seamark C., Su X., Veerareddy S., Searles G., Sudnik W., Mino M. V., Seidl K. -H., Sukles K., Venkataraman A., Seidman B., Sun X., Verdecchia P., Sek J., Swart H., Versaci F., Sekaran L., Szavits-Nossan J., Vester E. G., Serrati C., Taggeselle J., Vial H., Shah N., Takagi Y., Victory J., Shah V., Takhar A. P. S., Villamil A., Shah A., Tamm A., Vincent M., Shah S., Tanaka K., Vlastaris A., Sharma V. K., Tanawuttiwat T., Dahl J., Shaw L., Tang S., Vora K., Sheikh K. H., Tang A., Vranian R. B., Shimizu N., Tarsi G., Wakefield P., Shimomura H., Tassinari T., Wang N., Shin D. -G., Tayal A., Wang M., Shin E. -S., Tayebjee M., Wang X., Shite J., Berg J. M., Wang F., Sibilio G., Tesloianu D., Wang T., Silver F., The S. H. K., Warner A. L., Sime I., Thomas D., Watanabe K., Simmers T. A., Timsit S., Wei J., Singh N., Tobaru T., Weimar C., Siostrzonek P., Tomasik A. R., Weiner S., Smadja D., Torosoff M., Weinrich R., Smith D. W., Touze E., Wen M. -S., Snitman M., Trendafilova E., Wiemer M., Filho D. S., Tsai W. K., Wiggers P., Soda H., Tse H. F., Wilke A., Sofley C., Tsutsui H., Williams D., Williams M. L., Yan P. Y. B., Zhang P., Witzenbichler B., Yang T., Zhang J., Wong B., Yao J., Zhao S. P., Wong K. S. L., Yeh K. -H., Zhao Y., Wozakowska-Kaplon B., Yin W. H., Zhao Z., Wu S., Yotov Y., Zheng Y., Wu R. C., Zahn R., Zhou J., Wunderlich S., Zarich S., Zimmermann S., Wyatt N., Zenin S., Zini A., Wylie J., Zeuthen E. L., Zizzo S., Xu Y., Zhang H., Zong W., Xu X., Zhang D., Zukerman L. S., Yamanoue H., Zhang X., Yamashita T., Cardiology, ACS - Heart failure & arrhythmias, Lip G.Y.H., Kotalczyk A., Teutsch C., Diener H.-C., Dubner S.J., Halperin J.L., Ma C.-S., Rothman K.J., Marler S., Gurusamy V.K., Huisman M.V., Abban D.W., Aziz E., Kalan M.B., Abdul N., Backes L.M., Bradman D., Abud A.M., Badings E., Brautigam D., Adams F., Bagni E., Breton N., Addala S., Baker S.H., Brouwers P.J.A.M., Adragao P., Bala R., Browne K., Ageno W., Baldi A., Cortada J.B., Aggarwal R., Bando S., Bruni A., Agosti S., Banerjee S., Brunschwig C., Agostoni P., Bank A., Buathier H., Aguilar F., Esquivias G.B., Buhl A., Linares J.A., Barr C., Bullinga J., Aguinaga L., Bartlett M., Cabrera J.W., Ahmed J., Basic Kes V., Caccavo A., Aiello A., Baula G., Cai S., Ainsworth P., Behrens S., Caine S., Aiub J.R., Bell A., Calo L., Al-Dallow R., Benedetti R., Calvi V., Alderson L., Mazuecos J.B., Sanchez M.C., Velasco J.A.A., Benhalima B., Candeias R., Alexopoulos D., Bergler-Klein J., Capuano V., Manterola F.A., Berneau J.-B., Capucci A., Aliyar P., Bernstein R.A., Caputo R., Alonso D., Berrospi P., Rizo T.C., da Costa F.A.A., Berti S., Cardona F., Amado J., Berz A., da Costa Darrieux F.C., Amara W., Best E., Vera Y.C.D., Amelot M., Bettencourt P., Carolei A., Amjadi N., Betzu R., Carreno S., Ammirati F., Bhagwat R., Carvalho P., Andrade M., Bhatta L., Cary S., Andrawis N., Biscione F., Casu G., Annoni G., Bisignani G., Cavallini C., Ansalone G., Black T., Cayla G., Ariani M.K., Bloch M.J., Celentano A., Arias J.C., Bloom S., Cha T.-J., Armero S., Blumberg E., Cha K.S., Arora C., Bo M., Chae J.K., Aslam M.S., Bohmer E., Chalamidas K., Asselman M., Bollmann A., Challappa K., Audouin P., Bongiorni M.G., Chand S.P., Augenbraun C., Boriani G., Chandrashekar H., Aydin S., Boswijk D.J., Chartier L., Bott J., Chatterjee K., Ayryanova I., Bottacchi E., Ayala C.A.C., Cheema A., Davis G., Evonich R., Davy J.-M., Evseeva O., Chen L., Dayer M., Ezhov A., Chen S.-A., De Biasio M., Fahmy R., Chen J.H., De Bonis S., Fang Q., Chiang F.-T., De Caterina R., Farsad R., Chiarella F., De Franceschi T., Fauchier L., Chih-Chan L., de Groot J.R., Favale S., Cho Y.K., De Horta J., Fayard M., Choi J.-I., De La Briolle A., Fedele J.L., Choi D.J., de la Pena Topete G., Fedele F., Chouinard G., de Paola A.A.V., Fedorishina O., Chow D.H.-F., de Souza W., Fera S.R., Chrysos D., de Veer A., Ferreira L.G.G., Chumakova G., De Wolf L., Ferreira J., Valenzuela E.J.J.R.C., Decoulx E., Ferri C., Nica N.C., Deepak S., Ferrier A., Cislowski D.J., Defaye P., Ferro H., Clay A., Munoz F.D.-C., Finsen A., Clifford P., Brkljacic D.D., First B., Cohen A., Deumite N.J., Fischer S., Cohen M., Di Legge S., Fonseca C., Cohen S., Diemberger I., Almeida L.F., Colivicchi F., Dietz D., Forman S., Collins R., Dionisio P., Frandsen B., Colonna P., Dong Q., French W., Compton S., dos Santos F.R., Friedman K., Connolly D., Dotcheva E., Friese A., Conti A., Doukky R., Fruntelata A.G., Buenostro G.C., D'Souza A., Fujii S., Coodley G., Dubrey S., Fumagalli S., Cooper M., Ducrocq X., Fundamenski M., Coronel J., Dupljakov D., Furukawa Y., Corso G., Duque M., Gabelmann M., Sales J.C., Dutta D., Gabra N., Cottin Y., Duvilla N., Gadsboll N., Covalesky J., Duygun A., Galinier M., Cracan A., Dziewas R., Gammelgaard A., Crea F., Eaton C.B., Ganeshkumar P., Crean P., Eaves W., Gans C., Crenshaw J., Ebels-Tuinbeek L.A., Quintana A.G., Cullen T., Ehrlich C., Gartenlaub O., Darius H., Eichinger-Hasenauer S., Gaspardone A., Dary P., Eisenberg S.J., Genz C., Dascotte O., Jabali A.E., Georger F., Dauber I., Shahawy M.E., Georges J.-L., Davalos V., Hernandes M.E., Georgeson S., Davies R., Izal A.E., Giedrimas E., Gierba M., Haruna T., Jarmukli N., Ortega I.G., Hayek E., Jeanfreau R.J., Gillespie E., Healey J., Jenkins R.D., Giniger A., Hearne S., Sanchez C.J., Giudici M.C., Heffernan M., Jimenez J., Gkotsis A., Heggelund G., Jobe R., Glotzer T.V., Heijmeriks J.A., Joen-Jakobsen T., Gmehling J., Hemels M., Jones N., Gniot J., Hendriks I., Jorge J.C.M., Goethals P., Henein S., Jouve B., Goldbarg S., Her S.-H., Jung B.C., Goldberg R., Hermany P., Jung K.T., Goldmann B., Del Rio J.E.H., Jung W., Golitsyn S., Higashino Y., Kachkovskiy M., Gomez S., Hill M., Kafkala K., Mesa J.G., Hisadome T., Kalinina L., Gonzalez V.B., Hishida E., Kallmunzer B., Hermosillo J.A.G., Hoffer E., Kamali F., Lopez V.M.G., Hoghton M., Kamo T., Gorka H., Hong K., Kampus P., Gornick C., Hong S., Kashou H., Gorog D., Horbach S., Kastrup A., Gottipaty V., Horiuchi M., Katsivas A., Goube P., Hou Y., Kaufman E., Goudevenos I., Hsing J., Kawai K., Graham B., Huang C.-H., Kawajiri K., Greer G.S., Huckins D., Kazmierski J.F., Gremmler U., Hughes K., Keeling P., Grena P.G., Huizinga A., Saraiva J.F.K., Grond M., Hulsman E.L., Ketova G., Gronda E., Hung K.-C., Khaira A.S., Gronefeld G., Hwang G.-S., Khripun A., Gu X., Ikpoh M., Kim D.-I., Torres I.G.T., Imberti D., Kim Y.H., Guardigli G., Ince H., Kim N.H., Guevara C., Indolfi C., Kim D.K., Guignier A., Inoue S., Kim J.S., Gulizia M., Irles D., Gumbley M., Iseki H., Kim K.S., Gunther A., Israel C.N., Kim J., Ha A., Iteld B., Kinova E., Hahalis G., Iyer V., Klein A., Hakas J., Jackson-Voyzey E., Kmetzo J.J., Hall C., Jaffrani N., Kneller G.L., Han B., Jager F., Knezevic A., Han S., James M., Koh S.M.A., Hargrove J., Jang S.-W., Koide S., Hargroves D., Jaramillo N., Kollias A., Kooistra J.A., Li W., McClure J., Koons J., Li X., McCormack T., Koschutnik M., Lichy C., McGarity W., Kostis W.J., Lieber I., McIntyre H., Kovacic D., Rodriguez R.H.L., McLaurin B., Kowalczyk J., Lin H., Alvaro F., Palomino M., Koziolova N., Melandri F., Kraft P., Liu F., Meno H., Kragten J.A., Liu H., Menzies D., Krantz M., Esperon G.L., Mercader M., Krause L., Navarro N.L., Meyer C., Krenning B.J., Lo E., Meyer B.J., Krikke F., Lokshyn S., Miarka J., Kromhout Z., Lopez A., Mibach F., Krysiak W., Lopez-Sendon J.L., Michalski D., Kumar P., Filho A.M.L., Michel P., Kumler T., Lorraine R.S., Chreih R.M., Kuniss M., Luengas C.A., Luengas A., Mikdadi G., Kuo J.-Y., Luke R., Mikus M., Kuppers A., Luo M., Milicic D., Kurrelmeyer K., Lupovitch S., Militaru C., Kwak C.H., Lyrer P., Minaie S., Laboulle B., Ma C., Minescu B., Labovitz A., Ma G., Mintale I., Ter Lai W., Madariaga I., Mirault T., Lam A., Maeno K., Mirro M.J., Lam Y.Y., Magnin D., Mistry D., Lanas Zanetti F., Maid G., Miu N.V., Landau C., Mainigi S.K., Miyamoto N., Landini G., Makaritsis K., Moccetti T., Lanna Figueiredo E., Malhotra R., Mohammed A., Larsen T., Manning R., Nor A.M., Lavandier K., Manolis A., Mollerus M., LeBlanc J., Hurtado H.A.M., Molon G., Lee M.H., Mantas I., Mondillo S., Lee C.-H., Jattin F.M., Moniz P., Lehman J., Maqueda V., Mont L., Leitao A., Marchionni N., Montagud V., Lellouche N., Ortuno F.M., Montana O., Lelonek M., Santana A.M., Monti C., Lenarczyk R., Martinez J., Moretti L., Lenderink T., Maskova P., Mori K., Gonzalez S.L., Hernandez N.M., Moriarty A., Leong-Sit P., Matsuda K., Morka J., Leschke M., Maurer T., Moschini L., Ley N., Mauro C., Moschos N., Li Z., May E., Mugge A., Mayer N., Mulhearn T.J., Muresan C., Jose E.P., Precoma D.B., Muriago M., Padilla F.G.P., Prelle A., Musial W., Rios V.P., Prodafikas J., Musser C.W., Pajes G., Protasov K., Musumeci F., Pandey A.S., Pye M., Nageh T., Paparella G., Qiu Z., Nakagawa H., Paris F., Quedillac J.-M., Nakamura Y., Park H.W., Raev D., Nakayama T., Park J.S., Grado C.A.R., Nam G.-B., Parthenakis F., Rahimi S., Nanna M., Passamonti E., Raisaro A., Natarajan I., Patel R.J., Rama B., Nayak H.M., Patel J., Ramos R., Naydenov S., Patel M., Ranieri M., Nazlic J., Patrick J., Raposo N., Nechita A.C., Jimenez R.P., Rashba E., Nechvatal L., Paz A., Rauch-Kroehnert U., Negron S.A., Pengo V., Reddy R., Neiman J., Pentz W., Renda G., Neuenschwander F.C., Perez B., Reza S., Neves D., Rios A.M.P., Ria L., Neykova A., Perez-Cabezas A., Richter D., Miguel R.N., Perlman R., Rickli H., Nijmeh G., Persic V., Rieker W., Nizov A., Perticone F., Vera T.R., Campos R.N., Peters T.K., Ritt L.E., Nossan J., Petkar S., Roberts D., Novikova T., Pezo L.F., Briones I.R., Nowalany-Kozielska E., Pflucke C., Escudero A.E.R., Nsah E., Pham D.N., Pascual C.R., Fragoso J.C.N., Phillips R.T., Roman M., Nurgalieva S., Phlaum S., Romeo F., Nuyens D., Pieters D., Ronner E., Nyvad O., Pineau J., Roux J.-F., de Los Rios Ibarra M.O., Pinter A., Rozkova N., O'Donnell P., Pinto F., Rubacek M., O'Donnell M., Pisters R., Rubalcava F., Oh S., Pivac N., Russo A.M., Oh Y.S., Pocanic D., Rutgers M.P., Oh D., Podoleanu C., Rybak K., O'Hara G., Politano A., Said S., Oikonomou K., Poljakovic Z., Sakamoto T., Olivares C., Pollock S., Salacata A., Oliver R., Garcea J.P., Salem A., Ruiz R.O., Poppert H., Bodes R.S., Olympios C., Porcu M., Saltzman M.A., Omaszuk-Kazberuk A., Reino A.P., Salvioni A., Asensi J.O., Prasad N., Vallejo G.S., Fernandez M.S., Sokal A., Tu T.M., Saporito W.F., Yan Y.S.O., Tuininga Y., Sarikonda K., Sotolongo R., Turakhia M., Sasaoka T., de Souza O.F., Turk S., Sati H., Sparby J.A., Turner W., Savelieva I., Spinar J., Tveit A., Scala P.-J., Sprigings D., Tytus R., Schellinger P., Spyropoulos A.C., Valadao C., Scherr C., Stakos D., van Bergen P.F.M.M., Schmitz L., Steinwender C., van de Borne P., Schmitz K.-H., Stergiou G., van den Berg B.J., Schmitz B., Stiell I., van der Zwaan C., Schnabel T., Stoddard M., Van Eck M., Schnupp S., Stoikov A., Vanacker P., Schoeniger P., Streb W., Vasilev D., Schon N., Styliadis I., Vasilikos V., Schwimmbeck P., Su G., Vasilyev M., Seamark C., Su X., Veerareddy S., Searles G., Sudnik W., Mino M.V., Seidl K.-H., Sukles K., Venkataraman A., Seidman B., Sun X., Verdecchia P., Sek J., Swart H., Versaci F., Sekaran L., Szavits-Nossan J., Vester E.G., Serrati C., Taggeselle J., Vial H., Shah N., Takagi Y., Victory J., Shah V., Takhar A.P.S., Villamil A., Shah A., Tamm A., Vincent M., Shah S., Tanaka K., Vlastaris A., Sharma V.K., Tanawuttiwat T., Dahl J., Shaw L., Tang S., Vora K., Sheikh K.H., Tang A., Vranian R.B., Shimizu N., Tarsi G., Wakefield P., Shimomura H., Tassinari T., Wang N., Shin D.-G., Tayal A., Wang M., Shin E.-S., Tayebjee M., Wang X., Shite J., Berg J.M., Wang F., Sibilio G., Tesloianu D., Wang T., Silver F., The S.H.K., Warner A.L., Sime I., Thomas D., Watanabe K., Simmers T.A., Timsit S., Wei J., Singh N., Tobaru T., Weimar C., Siostrzonek P., Tomasik A.R., Weiner S., Smadja D., Torosoff M., Weinrich R., Smith D.W., Touze E., Wen M.-S., Snitman M., Trendafilova E., Wiemer M., Filho D.S., Tsai W.K., Wiggers P., Soda H., Tse H.F., Wilke A., Sofley C., Tsutsui H., Williams D., Williams M.L., Yan P.Y.B., Zhang P., Witzenbichler B., Yang T., Zhang J., Wong B., Yao J., Zhao S.P., Wong K.S.L., Yeh K.-H., Zhao Y., Wozakowska-Kaplon B., Yin W.H., Zhao Z., Wu S., Yotov Y., Zheng Y., Wu R.C., Zahn R., Zhou J., Wunderlich S., Zarich S., Zimmermann S., Wyatt N., Zenin S., Zini A., Wylie J., Zeuthen E.L., Zizzo S., Xu Y., Zhang H., Zong W., Xu X., Zhang D., Zukerman L.S., Yamanoue H., Zhang X., and Yamashita T.
- Subjects
Apixaban ,Atrial fibrillation ,Dabigatran ,Non-vitamin K antagonists ,Rivaroxaban ,Pyridones ,Medizin ,Myocardial Infarction ,Administration, Oral ,Anticoagulants ,Hemorrhage ,General Medicine ,Non-vitamin K antagonist ,Stroke ,Clinical Trials, Phase III as Topic ,Humans ,Prospective Studies ,Registries ,Cardiology and Cardiovascular Medicine - Abstract
Background and purpose Prospectively collected data comparing the safety and effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective was to directly compare the effectiveness and safety of NOACs in patients with newly diagnosed atrial fibrillation (AF). Methods In GLORIA-AF, a large, prospective, global registry program, consecutive patients with newly diagnosed AF were followed for 3 years. The comparative analyses for (1) dabigatran vs rivaroxaban or apixaban and (2) rivaroxaban vs apixaban were performed on propensity score (PS)-matched patient sets. Proportional hazards regression was used to estimate hazard ratios (HRs) for outcomes of interest. Results The GLORIA-AF Phase III registry enrolled 21,300 patients between January 2014 and December 2016. Of these, 3839 were prescribed dabigatran, 4015 rivaroxaban and 4505 apixaban, with median ages of 71.0, 71.0, and 73.0 years, respectively. In the PS-matched set, the adjusted HRs and 95% confidence intervals (CIs) for dabigatran vs rivaroxaban were, for stroke: 1.27 (0.79–2.03), major bleeding 0.59 (0.40–0.88), myocardial infarction 0.68 (0.40–1.16), and all-cause death 0.86 (0.67–1.10). For the comparison of dabigatran vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 1.16 (0.76–1.78), myocardial infarction 0.84 (0.48–1.46), major bleeding 0.98 (0.63–1.52) and all-cause death 1.01 (0.79–1.29). For the comparison of rivaroxaban vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 0.78 (0.52–1.19), myocardial infarction 0.96 (0.63–1.45), major bleeding 1.54 (1.14–2.08), and all-cause death 0.97 (0.80–1.19). Conclusions Patients treated with dabigatran had a 41% lower risk of major bleeding compared with rivaroxaban, but similar risks of stroke, MI, and death. Relative to apixaban, patients treated with dabigatran had similar risks of stroke, major bleeding, MI, and death. Rivaroxaban relative to apixaban had increased risk for major bleeding, but similar risks for stroke, MI, and death. Registration URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01468701, NCT01671007. Date of registration: September 2013. Graphical abstract
- Published
- 2022
- Full Text
- View/download PDF
26. Anti-inflammatory therapies in patients with cardiovascular disease: new evidence, clinical implications and perspectives
- Author
-
Gragnano F., Calabro P., De Sio V., Imazio M., Patti G., De Caterina R., Filardi P. P., Leonardi S., Gragnano, F., Calabro, P., De Sio, V., Imazio, M., Patti, G., De Caterina, R., Filardi, P. P., and Leonardi, S.
- Subjects
Inflammation ,Anakinra ,Ziltivekimab ,Canakinumab ,Interleukin ,Colchicine ,Residual risk - Abstract
Inflammation plays an important role in cardiovascular disease. Growing evidence suggests a profound involvement of the inflammatory response in the development and progression of atherosclerosis and its complications. In patients with atherosclerotic cardiovascular disease (ASCVD), residual cardiovascular risk often remains high despite optimal medical therapy and the achievement of the therapeutic targets recommended by current guidelines. Among the multiple components of residual risk, residual inflammatory risk, assessed by plasma levels of high-sensitivity C-reactive protein, has shown a strong association with the incidence of cardiovascular events. Recent studies suggest that therapeutic modulation of inflammation, particularly the interleukin (IL)-1/IL-6 pathway, is a promising strategy for the prevention and treatment of cardiovascular and kidney diseases. This review aims to discuss pragmatically the interaction between inflammation and ASCVD, describe current evidence on anti-inflammatory therapies in patients with cardiovascular and renal diseases, and outline the potential implications of these new therapeutic approaches in contemporary and future practice.
- Published
- 2022
27. Increased left atrial size in obese children and its association with insulin resistance: a pilot study
- Author
-
Marcovecchio, M. L., Gravina, M., Gallina, S., D’Adamo, E., De Caterina, R., Chiarelli, F., Mohn, A., and Renda, G.
- Published
- 2016
- Full Text
- View/download PDF
28. Clopidogrel “resistance”: Pre- vs post-receptor determinants
- Author
-
Hurst, N.L., Nooney, V.B., Raman, B., Chirkov, Y.Y., De Caterina, R., and Horowitz, J.D.
- Published
- 2013
- Full Text
- View/download PDF
29. Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study
- Author
-
Castelnuovo, A, Costanzo, S, Antinori, A, Berselli, N, Blandi, L, Bruno, R, Cauda, R, Guaraldi, G, Menicanti, L, My, I, Parruti, G, Patti, G, Perlini, S, Santilli, F, Signorelli, C, Spinoni, E, Stefanini, G, Vergori, A, Ageno, W, Agodi, A, Aiello, L, Agostoni, P, Moghazi, S, Astuto, M, Aucella, F, Barbieri, G, Bartoloni, A, Bonaccio, M, Bonfanti, P, Cacciatore, F, Caiano, L, Cannata, F, Carrozzi, L, Cascio, A, Ciccullo, A, Cingolani, A, Cipollone, F, Colomba, C, Crosta, F, Pra, C, Danzi, G, D'Ardes, D, Donati, K, Giacomo, P, Gennaro, F, Tano, G, D'Offizi, G, Filippini, T, Fusco, F, Gentile, I, Gialluisi, A, Gini, G, Grandone, E, Grisafi, L, Guarnieri, G, Lamonica, S, Landi, F, Leone, A, Maccagni, G, Maccarella, S, Madaro, A, Mapelli, M, Maragna, R, Marra, L, Maresca, G, Marotta, C, Mastroianni, F, Mazzitelli, M, Mengozzi, A, Menichetti, F, Meschiari, M, Minutolo, F, Montineri, A, Mussinelli, R, Mussini, C, Musso, M, Odone, A, Olivieri, M, Pasi, E, Petri, F, Pinchera, B, Pivato, C, Poletti, V, Ravaglia, C, Rinaldi, M, Rognoni, A, Rossato, M, Rossi, I, Rossi, M, Sabena, A, Salinaro, F, Sangiovanni, V, Sanrocco, C, Scorzolini, L, Sgariglia, R, Simeone, P, Spinicci, M, Trecarichi, E, Venezia, A, Veronesi, G, Vettor, R, Vianello, A, Vinceti, M, Vocciante, L, De Caterina, R, Iacoviello, L, Castelnuovo A. D., Costanzo S., Antinori A., Berselli N., Blandi L., Bruno R., Cauda R., Guaraldi G., Menicanti L., My I., Parruti G., Patti G., Perlini S., Santilli F., Signorelli C., Spinoni E., Stefanini G. G., Vergori A., Ageno W., Agodi A., Aiello L., Agostoni P., Moghazi S. A., Astuto M., Aucella F., Barbieri G., Bartoloni A., Bonaccio M., Bonfanti P., Cacciatore F., Caiano L., Cannata F., Carrozzi L., Cascio A., Ciccullo A., Cingolani A., Cipollone F., Colomba C., Crosta F., Pra C. D., Danzi G. B., D'Ardes D., Donati K. D. G., Giacomo P. D., Gennaro F. D., Tano G. D., D'Offizi G., Filippini T., Fusco F. M., Gentile I., Gialluisi A., Gini G., Grandone E., Grisafi L., Guarnieri G., Lamonica S., Landi F., Leone A., Maccagni G., Maccarella S., Madaro A., Mapelli M., Maragna R., Marra L., Maresca G., Marotta C., Mastroianni F., Mazzitelli M., Mengozzi A., Menichetti F., Meschiari M., Minutolo F., Montineri A., Mussinelli R., Mussini C., Musso M., Odone A., Olivieri M., Pasi E., Petri F., Pinchera B., Pivato C. A., Poletti V., Ravaglia C., Rinaldi M., Rognoni A., Rossato M., Rossi I., Rossi M., Sabena A., Salinaro F., Sangiovanni V., Sanrocco C., Scorzolini L., Sgariglia R., Simeone P. G., Spinicci M., Trecarichi E. M., Venezia A., Veronesi G., Vettor R., Vianello A., Vinceti M., Vocciante L., De Caterina R., Iacoviello L., Castelnuovo, A, Costanzo, S, Antinori, A, Berselli, N, Blandi, L, Bruno, R, Cauda, R, Guaraldi, G, Menicanti, L, My, I, Parruti, G, Patti, G, Perlini, S, Santilli, F, Signorelli, C, Spinoni, E, Stefanini, G, Vergori, A, Ageno, W, Agodi, A, Aiello, L, Agostoni, P, Moghazi, S, Astuto, M, Aucella, F, Barbieri, G, Bartoloni, A, Bonaccio, M, Bonfanti, P, Cacciatore, F, Caiano, L, Cannata, F, Carrozzi, L, Cascio, A, Ciccullo, A, Cingolani, A, Cipollone, F, Colomba, C, Crosta, F, Pra, C, Danzi, G, D'Ardes, D, Donati, K, Giacomo, P, Gennaro, F, Tano, G, D'Offizi, G, Filippini, T, Fusco, F, Gentile, I, Gialluisi, A, Gini, G, Grandone, E, Grisafi, L, Guarnieri, G, Lamonica, S, Landi, F, Leone, A, Maccagni, G, Maccarella, S, Madaro, A, Mapelli, M, Maragna, R, Marra, L, Maresca, G, Marotta, C, Mastroianni, F, Mazzitelli, M, Mengozzi, A, Menichetti, F, Meschiari, M, Minutolo, F, Montineri, A, Mussinelli, R, Mussini, C, Musso, M, Odone, A, Olivieri, M, Pasi, E, Petri, F, Pinchera, B, Pivato, C, Poletti, V, Ravaglia, C, Rinaldi, M, Rognoni, A, Rossato, M, Rossi, I, Rossi, M, Sabena, A, Salinaro, F, Sangiovanni, V, Sanrocco, C, Scorzolini, L, Sgariglia, R, Simeone, P, Spinicci, M, Trecarichi, E, Venezia, A, Veronesi, G, Vettor, R, Vianello, A, Vinceti, M, Vocciante, L, De Caterina, R, Iacoviello, L, Castelnuovo A. D., Costanzo S., Antinori A., Berselli N., Blandi L., Bruno R., Cauda R., Guaraldi G., Menicanti L., My I., Parruti G., Patti G., Perlini S., Santilli F., Signorelli C., Spinoni E., Stefanini G. G., Vergori A., Ageno W., Agodi A., Aiello L., Agostoni P., Moghazi S. A., Astuto M., Aucella F., Barbieri G., Bartoloni A., Bonaccio M., Bonfanti P., Cacciatore F., Caiano L., Cannata F., Carrozzi L., Cascio A., Ciccullo A., Cingolani A., Cipollone F., Colomba C., Crosta F., Pra C. D., Danzi G. B., D'Ardes D., Donati K. D. G., Giacomo P. D., Gennaro F. D., Tano G. D., D'Offizi G., Filippini T., Fusco F. M., Gentile I., Gialluisi A., Gini G., Grandone E., Grisafi L., Guarnieri G., Lamonica S., Landi F., Leone A., Maccagni G., Maccarella S., Madaro A., Mapelli M., Maragna R., Marra L., Maresca G., Marotta C., Mastroianni F., Mazzitelli M., Mengozzi A., Menichetti F., Meschiari M., Minutolo F., Montineri A., Mussinelli R., Mussini C., Musso M., Odone A., Olivieri M., Pasi E., Petri F., Pinchera B., Pivato C. A., Poletti V., Ravaglia C., Rinaldi M., Rognoni A., Rossato M., Rossi I., Rossi M., Sabena A., Salinaro F., Sangiovanni V., Sanrocco C., Scorzolini L., Sgariglia R., Simeone P. G., Spinicci M., Trecarichi E. M., Venezia A., Veronesi G., Vettor R., Vianello A., Vinceti M., Vocciante L., De Caterina R., and Iacoviello L.
- Abstract
Background: Hydroxychloroquine (HCQ) was proposed as potential treatment for COVID-19. Objective: We set-up a multicenter Italian collaboration to investigate the relationship between HCQ therapy and COVID-19 in-hospital mortality. Methods: In a retrospective observational study, 3,451 unselected patients hospitalized in 33 clinical centers in Italy, from February 19, 2020 to May 23, 2020, with laboratory-confirmed SARS-CoV-2 infection, were analyzed. The primary end-point in a time-to event analysis was in-hospital death, comparing patients who received HCQ with patients who did not. We used multivariable Cox proportional-hazards regression models with inverse probability for treatment weighting by propensity scores, with the addition of subgroup analyses. Results: Out of 3,451 COVID-19 patients, 76.3% received HCQ. Death rates (per 1,000 person-days) for patients receiving or not HCQ were 8.9 and 15.7, respectively. After adjustment for propensity scores, we found 30% lower risk of death in patients receiving HCQ (HR=0.70; 95%CI: 0.59 to 0.84; E-value=1.67). Secondary analyses yielded similar results. The inverse association of HCQ with inpatient mortality was particularly evident in patients having elevated C-reactive protein at entry. Conclusions: HCQ use was associated with a 30% lower risk of death in COVID-19 hospitalized patients. Within the limits of an observational study and awaiting results from randomized controlled trials, these data do not discourage the use of HCQ in inpatients with COVID-19.
- Published
- 2020
30. Grey zones on dual antiplatelet therapy. Expert opinion
- Author
-
De Servi, S, Sciatti, E, Temporelli, P, De Caterina, R, Prati, F, Zito, G, Carugo, S, De Biase, L, Senni, M, Rossini, R, De Servi S, Sciatti E, Temporelli PL, De Caterina R, Prati F, Zito GB, Carugo S, De Biase L, Senni M, Rossini R, De Servi, S, Sciatti, E, Temporelli, P, De Caterina, R, Prati, F, Zito, G, Carugo, S, De Biase, L, Senni, M, Rossini, R, De Servi S, Sciatti E, Temporelli PL, De Caterina R, Prati F, Zito GB, Carugo S, De Biase L, Senni M, and Rossini R
- Abstract
Clinical guidelines, while representing an objective reference to perform appropriate treatment choices, contain grey zones, where recommendations are not supported by solid evidence. In a conference held in Bergamo in October 2018, an attempt was made to highlight some of the main gray zones in Cardiology and, through a comparison between experts, to draw shared conclusions that can illuminate our clinical practice. This manuscript contains the statements of the symposium concerning the controversies regarding dual antiplatelet therapy (DAPT). The manuscript represents the organization of the meeting, with an initial review of current guidelines on this topic, followed by an expert presentation of pros (white) and cons (black) related to the identified "gaps of evidence". For every issue is then reported the response derived from the votes of the experts and the public, the discussion and, finally, the highlights, which are intended as practical "take home messages" to be used in everyday clinical practice. The first topic concerns the utility of scores to shorten the duration of DAPT in patients at high bleeding risk. The second issue examines the appropriateness of the level of evidence to prolong DAPT beyond 1 year in patients at high ischemic risk. The last "gap in evidence" concerns the possibility of adopting the single antiplatelet therapy plus an anticoagulant vs the triple therapy in patients with atrial fibrillation and acute coronary syndrome. The work has also been implemented with evidences deriving from important randomized studies published after the date of the Conference.
- Published
- 2020
31. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era
- Author
-
De Rosa, S, Spaccarotella, C, Basso, C, Calabro, M, Curcio, A, Filardi, P, Mancone, M, Mercuro, G, Muscoli, S, Nodari, S, Pedrinelli, R, Sinagra, G, Indolfi, C, Angelini, F, Barilla, F, Bartorelli, A, Benedetto, F, Bernabo, P, Bolognese, L, Briani, M, Cacciavillani, L, Calabrese, A, Calabro, P, Caliendo, L, Calo, L, Casella, G, Casu, G, Cavallini, C, Ciampi, Q, Ciccone, M, Comito, M, Corrada, E, Crea, F, D'Andrea, A, D'Urbano, M, De Caterina, R, De Ferrari, G, De Ponti, R, Della Mattia, A, DI Mario, C, Donnazzan, L, Esposito, G, Fedele, F, Ferraro, A, Galasso, G, Galie, N, Gnecchi, M, Golino, P, Golia, B, Guarini, P, Leonardi, S, Locuratolo, N, Luzza, F, Manganiello, V, Francesca Marchetti, M, Marenzi, G, Margonato, A, Meloni, L, Metra, M, Milo, M, Mongiardo, A, Monzo, L, Morisco, C, Novo, G, Pancaldi, S, Parollo, M, Paterno, G, Patti, G, Priori, S, Ravera, A, Giuseppe Rebuzzi, A, Rossi, M, Scherillo, M, Semprini, F, Senni, M, Sibilio, G, Siviglia, M, Tamburino, C, Tortorici, G, Versace, F, Villari, B, Volpe, M, De Rosa S., Spaccarotella C., Basso C., Calabro M. P., Curcio A., Filardi P. P., Mancone M., Mercuro G., Muscoli S., Nodari S., Pedrinelli R., Sinagra G., Indolfi C., Angelini F., Barilla F., Bartorelli A., Benedetto F., Bernabo P., Bolognese L., Briani M., Cacciavillani L., Calabrese A., Calabro P., Caliendo L., Calo L., Casella G., Casu G., Cavallini C., Ciampi Q., Ciccone M., Comito M., Corrada E., Crea F., D'Andrea A., D'Urbano M., De Caterina R., De Ferrari G., De Ponti R., Della Mattia A., DI Mario C., Donnazzan L., Esposito G., Fedele F., Ferraro A., Galasso G., Galie N., Gnecchi M., Golino P., Golia B., Guarini P., Leonardi S., Locuratolo N., Luzza F., Manganiello V., Francesca Marchetti M., Marenzi G., Margonato A., Meloni L., Metra M., Milo M., Mongiardo A., Monzo L., Morisco C., Novo G., Pancaldi S., Parollo M., Paterno G., Patti G., Priori S., Ravera A., Giuseppe Rebuzzi A., Rossi M., Scherillo M., Semprini F., Senni M., Sibilio G., Siviglia M., Tamburino C., Tortorici G., Versace F., Villari B., Volpe M., De Rosa, S, Spaccarotella, C, Basso, C, Calabro, M, Curcio, A, Filardi, P, Mancone, M, Mercuro, G, Muscoli, S, Nodari, S, Pedrinelli, R, Sinagra, G, Indolfi, C, Angelini, F, Barilla, F, Bartorelli, A, Benedetto, F, Bernabo, P, Bolognese, L, Briani, M, Cacciavillani, L, Calabrese, A, Calabro, P, Caliendo, L, Calo, L, Casella, G, Casu, G, Cavallini, C, Ciampi, Q, Ciccone, M, Comito, M, Corrada, E, Crea, F, D'Andrea, A, D'Urbano, M, De Caterina, R, De Ferrari, G, De Ponti, R, Della Mattia, A, DI Mario, C, Donnazzan, L, Esposito, G, Fedele, F, Ferraro, A, Galasso, G, Galie, N, Gnecchi, M, Golino, P, Golia, B, Guarini, P, Leonardi, S, Locuratolo, N, Luzza, F, Manganiello, V, Francesca Marchetti, M, Marenzi, G, Margonato, A, Meloni, L, Metra, M, Milo, M, Mongiardo, A, Monzo, L, Morisco, C, Novo, G, Pancaldi, S, Parollo, M, Paterno, G, Patti, G, Priori, S, Ravera, A, Giuseppe Rebuzzi, A, Rossi, M, Scherillo, M, Semprini, F, Senni, M, Sibilio, G, Siviglia, M, Tamburino, C, Tortorici, G, Versace, F, Villari, B, Volpe, M, De Rosa S., Spaccarotella C., Basso C., Calabro M. P., Curcio A., Filardi P. P., Mancone M., Mercuro G., Muscoli S., Nodari S., Pedrinelli R., Sinagra G., Indolfi C., Angelini F., Barilla F., Bartorelli A., Benedetto F., Bernabo P., Bolognese L., Briani M., Cacciavillani L., Calabrese A., Calabro P., Caliendo L., Calo L., Casella G., Casu G., Cavallini C., Ciampi Q., Ciccone M., Comito M., Corrada E., Crea F., D'Andrea A., D'Urbano M., De Caterina R., De Ferrari G., De Ponti R., Della Mattia A., DI Mario C., Donnazzan L., Esposito G., Fedele F., Ferraro A., Galasso G., Galie N., Gnecchi M., Golino P., Golia B., Guarini P., Leonardi S., Locuratolo N., Luzza F., Manganiello V., Francesca Marchetti M., Marenzi G., Margonato A., Meloni L., Metra M., Milo M., Mongiardo A., Monzo L., Morisco C., Novo G., Pancaldi S., Parollo M., Paterno G., Patti G., Priori S., Ravera A., Giuseppe Rebuzzi A., Rossi M., Scherillo M., Semprini F., Senni M., Sibilio G., Siviglia M., Tamburino C., Tortorici G., Versace F., Villari B., and Volpe M.
- Abstract
Aims: To evaluate the impact of the COVID-19 pandemic on patient admissions to Italian cardiac care units (CCUs). Methods and Results: We conducted a multicentre, observational, nationwide survey to collect data on admissions for acute myocardial infarction (AMI) at Italian CCUs throughout a 1 week period during the COVID-19 outbreak, compared with the equivalent week in 2019. We observed a 48.4% reduction in admissions for AMI compared with the equivalent week in 2019 (P < 0.001). The reduction was significant for both ST-segment elevation myocardial infarction [STEMI; 26.5%, 95% confidence interval (CI) 21.7-32.3; P = 0.009] and non-STEMI (NSTEMI; 65.1%, 95% CI 60.3-70.3; P < 0.001). Among STEMIs, the reduction was higher for women (41.2%; P = 0.011) than men (17.8%; P = 0.191). A similar reduction in AMI admissions was registered in North Italy (52.1%), Central Italy (59.3%), and South Italy (52.1%). The STEMI case fatality rate during the pandemic was substantially increased compared with 2019 [risk ratio (RR) = 3.3, 95% CI 1.7-6.6; P < 0.001]. A parallel increase in complications was also registered (RR = 1.8, 95% CI 1.1-2.8; P = 0.009). Conclusion: Admissions for AMI were significantly reduced during the COVID-19 pandemic across Italy, with a parallel increase in fatality and complication rates. This constitutes a serious social issue, demanding attention by the scientific and healthcare communities and public regulatory agencies.
- Published
- 2020
32. n-3 Fatty Acids and Platelet-Vessel Wall Interactions
- Author
-
De Caterina, R., Crepaldi, G., editor, De Caterina, R., editor, Kristensen, S. D., editor, and Schmidt, E. B., editor
- Published
- 1992
- Full Text
- View/download PDF
33. Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD)
- Author
-
Leonardis, D., Basta, G., Mallamaci, F., Cutrupi, S., Pizzini, P., Tripepi, R., Tripepi, G., De Caterina, R., and Zoccali, C.
- Published
- 2012
- Full Text
- View/download PDF
34. Effectiveness and safety of edoxaban in 27,333 patients from ETNA-AF with and without a history of intracranial haemorrhage after 2 years of treatment
- Author
-
Moser, J, primary, Unverdorben, M, additional, Wang, CC, additional, Bruggenjurgen, B, additional, Lee, BC, additional, Chen, C, additional, Pecen, L, additional, Yamashita, T, additional, De Caterina, R, additional, and Kirchhof, P, additional
- Published
- 2022
- Full Text
- View/download PDF
35. Coffee: Health Effects
- Author
-
Tofalo, R., primary, Renda, G., additional, De Caterina, R., additional, and Suzzi, G., additional
- Published
- 2016
- Full Text
- View/download PDF
36. Clinical experience with apixaban in atrial fibrillation: implications of AVERROES
- Author
-
De Caterina R
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Raffaele De CaterinaInstitute of Cardiology and Center of Excellence on Aging, G d’Annunzio University, Chieti, G Monasterio Foundation, Pisa, ItalyAbstract: Atrial fibrillation is an extremely common arrhythmia, which substantially increases the risk of stroke and thromboembolism. Prevention of stroke and thromboembolism is therefore an important part of the management of atrial fibrillation. Guidelines until now have recommended that patients with atrial fibrillation receive some form of antithrombotic therapy, ie, a vitamin K antagonist or aspirin, with a preference for anticoagulants in most cases. However, current treatments are suboptimal, and despite the recommendations, many patients do not receive adequate thromboprophylaxis, because they are considered, for various reasons, “unsuitable” to receive a vitamin K antagonist. In this patient population, apixaban, a new oral anticoagulant inhibiting activated coagulation factor X, administered in fixed doses and without anticoagulation monitoring, has undergone testing against aspirin in the recently published AVERROES trial. This paper addresses the strengths and limitations of this trial and the practical relevance of the new clinical information it provides.Keywords: atrial fibrillation, apixaban, thromboprophylaxis
- Published
- 2011
37. 1478Prognostic Value of Pulmonary Blood Volume by Contrast-Enhanced Magnetic Resonance Imaging in Heart Failure Outpatients – The PROVE-HF Study
- Author
-
Ricci, F., Barison, A., Todiere, G., Gaeta, R., Galllina, S., Emdin, M., De Caterina, R., and Aquaro, G.D.
- Published
- 2016
- Full Text
- View/download PDF
38. [Grey zones on dual antiplatelet therapy. Expert opinion]
- Author
-
De Servi S, Sciatti E, Temporelli PL, De Caterina R, Prati F, Zito GB, Carugo S, De Biase L, Senni M, Rossini R, De Servi, S, Sciatti, E, Temporelli, P, De Caterina, R, Prati, F, Zito, G, Carugo, S, De Biase, L, Senni, M, and Rossini, R
- Subjects
Antiplatelets ,Bleeding risk ,Direct oral anticoagulants ,Dual antiplatelet therapy ,Ischemic risk ,New oral anticoagulants ,PRECISE-DAPT ,Triple therapy ,Acute Coronary Syndrome ,Anticoagulants ,Atrial Fibrillation ,Dual Anti-Platelet Therapy ,Hemorrhage ,Humans ,Platelet Aggregation Inhibitors ,Practice Guidelines as Topic ,New oral anticoagulant ,Antiplatelet ,Direct oral anticoagulant - Abstract
Clinical guidelines, while representing an objective reference to perform appropriate treatment choices, contain grey zones, where recommendations are not supported by solid evidence. In a conference held in Bergamo in October 2018, an attempt was made to highlight some of the main gray zones in Cardiology and, through a comparison between experts, to draw shared conclusions that can illuminate our clinical practice. This manuscript contains the statements of the symposium concerning the controversies regarding dual antiplatelet therapy (DAPT). The manuscript represents the organization of the meeting, with an initial review of current guidelines on this topic, followed by an expert presentation of pros (white) and cons (black) related to the identified "gaps of evidence". For every issue is then reported the response derived from the votes of the experts and the public, the discussion and, finally, the highlights, which are intended as practical "take home messages" to be used in everyday clinical practice. The first topic concerns the utility of scores to shorten the duration of DAPT in patients at high bleeding risk. The second issue examines the appropriateness of the level of evidence to prolong DAPT beyond 1 year in patients at high ischemic risk. The last "gap in evidence" concerns the possibility of adopting the single antiplatelet therapy plus an anticoagulant vs the triple therapy in patients with atrial fibrillation and acute coronary syndrome. The work has also been implemented with evidences deriving from important randomized studies published after the date of the Conference.
- Published
- 2020
39. Cardiovascular morbidity and mortality related to non-alcoholic fatty liver disease: a systematic review and meta-analysis of prospective studies
- Author
-
Bisaccia, G, primary, Ricci, F, additional, Melchiorre, E, additional, Tana, C, additional, Renda, G, additional, Khanji, M Y, additional, Fedorowski, A, additional, De Caterina, R, additional, and Gallina, S, additional
- Published
- 2021
- Full Text
- View/download PDF
40. Edoxaban treatment in real-world practice is highly concordant with ESC atrial fibrillation guidelines: results from the non-interventional global ETNA-AF program
- Author
-
Morrone, D, primary, Chen, C, additional, Dinshaw, L, additional, Jiang, W, additional, Kim, Y.-H, additional, Kirchhof, P, additional, Koretsune, Y, additional, Pecen, L, additional, Reimitz, P.-E, additional, Wang, C.-C, additional, Yamashita, T, additional, Unverdorben, M, additional, and De Caterina, R, additional
- Published
- 2021
- Full Text
- View/download PDF
41. Telomerase and myocardin co-expressing mesenchymal cells increase survival and induce cardiac and vascular markers in cardiac stromal cells undergoing simulated ischemia/reperfusion
- Author
-
Madonna, R, primary, Guarnieri, S, additional, Csenger Kovacshazi, C, additional, Gorbe, A, additional, Giricz, Z, additional, Geng, Y J, additional, Mariggio, M A, additional, Ferdinandy, P, additional, and De Caterina, R, additional
- Published
- 2021
- Full Text
- View/download PDF
42. Prevention of contrast-induced nephropathy with urine alkalinization: the TEATE study
- Author
-
Lombardi, M, primary, Molisana, M, additional, Genovesi, E, additional, De Innocentiis, C, additional, Limbruno, U, additional, Misuraca, L, additional, Di Vito, L, additional, Zimarino, M, additional, Renda, G, additional, Di Nicola, M, additional, and De Caterina, R, additional
- Published
- 2021
- Full Text
- View/download PDF
43. Bone-vessels relationships: association between calcifications of the iliac arteries with vertebral fractures in hemodialysis patients – results from the VIKI study
- Author
-
Fusaro, M, primary, Tripepi, G, additional, Politi, C, additional, Aghi, A, additional, Taddei, F, additional, Schileo, E, additional, and De Caterina, R, additional
- Published
- 2021
- Full Text
- View/download PDF
44. Effectiveness and safety of edoxaban in atrial fibrillation patients from the ETNA-AF global registry
- Author
-
De Caterina, R, primary, Wang, R, additional, Shi, L, additional, Pecen, L, additional, Ye, X, additional, Reimitz, P.-E, additional, Chen, C, additional, Unverdorben, M, additional, and Giugliano, R.P, additional
- Published
- 2021
- Full Text
- View/download PDF
45. Sex-related differential susceptibility to ponatinib-induced cardiotoxicity and its relationship to modulation of Notch signaling in a murine model
- Author
-
Madonna, R, primary, Pieragostino, D, additional, Cufaro, M C, additional, Del Boccio, P, additional, Pucci, A, additional, Mattii, L, additional, Doria, V, additional, Cadeddu Dessalvi, C, additional, Zucchi, R, additional, Mercuro, G, additional, and De Caterina, R, additional
- Published
- 2021
- Full Text
- View/download PDF
46. Isolated exercise-induced pulmonary hypertension is associated with clinical worsening and poorer immunological control in hiv patients
- Author
-
Madonna, R, primary, Fabiani, S, additional, Morganti, R, additional, Forniti, A, additional, Menichetti, F, additional, and De Caterina, R, additional
- Published
- 2021
- Full Text
- View/download PDF
47. Temporal trend of clinical events in patients with atrial fibrillation on edoxaban therapy: results from the non-interventional global ETNA-AF program
- Author
-
Dinshaw, L, primary, Chen, C, additional, De Caterina, R, additional, Jiang, W, additional, Kim, Y.-H, additional, Koretsune, Y, additional, Morrone, D, additional, Pecen, L, additional, Reimitz, P.-E, additional, Wang, C.-C, additional, Yamashita, T, additional, Unverdorben, M, additional, and Kirchhof, P, additional
- Published
- 2021
- Full Text
- View/download PDF
48. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study
- Author
-
De Caterina, R., Kelly, P., Monteiro, P., Deharo, J. C., de Asmundis, C., López-de-Sá, E., Weiss, T. W., Waltenberger, J., Steffel, J., de Groot, J. R., Levy, P., Bakhai, A., Zierhut, W., Laeis, P., Reimitz, P. -E., Kirchhof, P., on behalf of the ETNA-AF-Europe investigators, Clinical sciences, Heartrhythmmanagement, Institute of Clinical Physiology, National Council of Research, NS Research, Novartis Institutes for BioMedical Research (NIBR), Division of Medicine, University College of London [London] (UCL), Neurovascular Clinical Science Unit, Catherine McAuley Centre, Mater Misericordiae University Hospital, Département de Cardiologie [Hôpital de la Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Laboratoire d'Economie de Dauphine (LEDa), Université Paris Dauphine-PSL, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), Laboratoire d'Economie et de Gestion des Organisations de Santé (Legos), Department of Medicine, Royal Free (DEPARTMENT OF MEDICINE, ROYAL FREE), Royal Free and University College London School of Medicine, Daiichi Sankyo Inc., Daiichi Sankyo Co., ACS - Heart failure & arrhythmias, Cardiology, University of Zurich, and De Caterina, Raffaele
- Subjects
Research design ,Time Factors ,medicine.drug_mechanism_of_action ,Pyridines ,Administration, Oral ,Major bleeding ,030204 cardiovascular system & hematology ,chemistry.chemical_compound ,0302 clinical medicine ,Edoxaban ,Stroke prevention ,Atrial Fibrillation ,Epidemiology ,Routine clinical practice ,Prospective Studies ,Registries ,030212 general & internal medicine ,Prospective cohort study ,Stroke ,[QFIN]Quantitative Finance [q-fin] ,Atrial fibrillation ,General Medicine ,3. Good health ,Europe ,JEL: I - Health, Education, and Welfare/I.I1 - Health/I.I1.I11 - Analysis of Health Care Markets ,Treatment Outcome ,ETNA-AF-Europe study ,Research Design ,10209 Clinic for Cardiology ,epidemiology ,Cardiology and Cardiovascular Medicine ,Registry ,medicine.medical_specialty ,Factor Xa Inhibitor ,610 Medicine & health ,Hemorrhage ,2705 Cardiology and Cardiovascular Medicine ,03 medical and health sciences ,Nonvitamin K antagonist oral anticoagulants ,Internal medicine ,medicine ,Humans ,cardiovascular diseases ,Safety outcomes ,business.industry ,PREFER in AF ,medicine.disease ,JEL: I - Health, Education, and Welfare/I.I1 - Health/I.I1.I12 - Health Behavior ,Thiazoles ,Real-world ,chemistry ,business ,Factor Xa Inhibitors - Abstract
AIM: Edoxaban, a nonvitamin K antagonist oral anticoagulant, is an oral factor Xa inhibitor approved for the prevention of stroke and systemic embolism in adult patients with atrial fibrillation and for the treatment and secondary prevention in adult patients with venous thromboembolism (VTE). This study details the design of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study - a postauthorization observational study, which is part of the postapproval plan for edoxaban agreed with the European Medicines Agency. METHODS: The ETNA-AF-Europe study (Clinicaltrials.gov: NCT02944019) is a multicenter, prospective, observational study that enrolled 13 980 patients with atrial fibrillation treated with edoxaban from 852 sites across 10 European countries (Austria, Belgium, Germany, Ireland, Italy, the Netherlands, Portugal, Spain, Switzerland, and the United Kingdom). Patients treated with edoxaban were prospectively enrolled and will be followed up for 4 years with yearly follow-up visits. ASSESSMENTS: The primary objective of the ETNA-AF-Europe study is to assess the real-world safety of edoxaban by evaluating bleeding events, including intracranial hemorrhage; drug-related adverse events, such as hepatic events; and cardiovascular and all-cause mortality. In addition, efficacy will be assessed by recording major adverse cardiovascular events including stroke, systemic embolic events, transient ischemic attacks, and also VTE episodes, acute coronary syndromes, and hospitalizations related to cardiovascular condition. Event rates will be compared with event rates reported in the PREvention oF thromboembolic events-European Registry in Atrial Fibrillation in atrial fibrillation (PREFER in AF) and PREFER in AF Prolongation registries, and in the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation - Thrombolysis in Myocardial Infarction 48 study datasets.
- Published
- 2019
- Full Text
- View/download PDF
49. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH: comment
- Author
-
HUSTED, S., LIP, G. Y. H., and DE CATERINA, R.
- Published
- 2015
- Full Text
- View/download PDF
50. La placca guarita: racconto di una storia a lieto fine, con implicazioni pratiche
- Author
-
Mascellanti, M., Fulgenzi, F., Carnesale, R., and De Caterina, R.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.